Lack of development of new antimicrobial drugs: A potential serious threat to public health

Lancet Infectious Diseases

Volumn 5, Issue 2, 2005, Pages 115-119

  Norrby, S Ragnar ^a   Nord, Carl Erik ^b   Finch, Roger ^c  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BETA LACTAM; CARBAPENEM; CEPHALOSPORIN; CHLORAMPHENICOL DERIVATIVE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERTAPENEM; GATIFLOXACIN; GLYCOPEPTIDE; GREPAFLOXACIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOGRAMIN DERIVATIVE; STREPTOMYCIN; SULFONAMIDE; TELITHROMYCIN; TETRACYCLINE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; BIOTECHNOLOGY; BRONCHITIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG USE; GENOMICS; HEALTH CARE COST; HUMAN; INFECTION; INVESTMENT; LICENSING; MALARIA; MEDICAL DOCUMENTATION; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH; QT PROLONGATION; REVIEW; SINUSITIS; THERAPY RESISTANCE; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 12944302098     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(05)70086-4     Document Type: Review

References (22)

1. Bax R, Mullan N, Verhoef J. The millennium bugs - the need for and development of new antibacterials. Int J Antimicrob Agents. 16:2000;51-59
2. Projan SJ. Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol. 6:2003;427-430
3. Nelson R. Antibiotic development pipeline runs dry. New drugs to fight resistant organisms are not being developed, experts say. Lancet. 362:2003;1726-1727
4. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE. Jr. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis. 38:2004;1279-1286
5. Cornaglia G, Lönnroth A, Struelens M. Report from a European conference on the role of research in combating antibiotic resistance, 2003. Clin Microbiol Infect. 10:2004;473-497
6. Kleinberg ML, Wanke LA. New approaches and technologies in drug design and discovery. Am J Health Syst Pharm. 15:1995;1341-1343
7. Haney SA, Alksne LE, Dunman PM, Murphy E, Projan SJ. Genomics in anti-infective drug discovery - getting to the endgame. Curr Pharm Des. 8:2002;1099-1118
8. Wenzel RP. The antibiotic pipeline - challenges, costs, and values. N Engl J Med. 351:2004;523-526
9. Beam TR Jr, Gilbert DN, Kunin CM. Guidelines for the evaluation of anti-infective drug products. Clin infect Dis. 15:(suppl 1):1992;S5-S32
10. Beam TR Jr, Gilbert DN, Lunin CM, European Working Party. European guidelines for the clinical evaluation of anti-infective drug products. Munich, Germany: European Society for Clinical Microbiology and Infectious Diseases; 1993.
11. Smucny J, Fahey T, Becker L, Glazier R, McIsaac W. Antibiotics for acute bronchitis. Cochrane Database Syst Rev. 2:2004;CD000245
12. Allegra L, Blasi F, de Bernadi B, Cosentini R, Tarisa P. Antibiotic treatment and baseline severity in acute exacerbations of chronic bronchitis: a re-evaluation of previously published data of a placebo-controlled randomized study. Pulm Pharmacol Ther. 14:2001;149-155
13. Black P, Staykova T, Chacko E, Ram FS, Poole P. Prophylactic antibiotic therapy for chronic bronchitis. Cochrane Database Syst Rev. 1:2003;CD004105
14. Williams JW Jr, Aguilar C, Cornell DED, et al. Antibiotics for acute maxillary sinusitis. Cochrane Database Syst Rev. 2:2003;CD000243
15. Galsziou PP, Mar CB, Sanders SL, Hayem M. Antibiotics for acute otitis media in children. Cochrane Database Syst Rev. 1:2004;CD000219
16. Anon. FDA gives new antibiotic mixed endorsement. Clin Infect Dis. 32:2001;i
17. Cars O, Mölstad S, Melander A. Variation in antibiotic use in the European Union. Lancet. 357:2001;1851-1853
18. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol. 2:2004;289-300
19. Committee for Proprietary Medicinal Products (CPMP). Points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products. London: The European Agency for the Evaluation of Medicinal Product: 2000; CPMP/EWP/2655/99.
20. Ferry SA, Holm SE, Stenlund H, Lundholm R, Monsen TJ. The natural course of uncomplicated lower urinary tract infection in women illustrated by a randomized placebo controlled study. Scand J Infect Dis. 36:2004;296-301
21. Swedish-Norwegian Consensus Group. Antibiotic prophylaxis in surgery: summary of a Swedish-Norwegian consensus conference. Scand J Infect Dis. 30:1998;547-557
22. Norrby SR. Evaluation of clinical trials of anti-infective drugs. In Armstrong D, Cohen J, eds. Infectious diseases. London: Mosby, Harcourt Publishers: 1999. 19.1-4.